5/10
11:25 am
anab
AnaptysBio, Inc. (NASDAQ: ANAB) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $34.00 price target on the stock.
Medium
Report
AnaptysBio, Inc. (NASDAQ: ANAB) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $34.00 price target on the stock.
5/9
07:44 pm
anab
AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates [Yahoo! Finance]
High
Report
AnaptysBio, Inc. (ANAB) Reports Q1 Loss, Tops Revenue Estimates [Yahoo! Finance]
5/9
04:35 pm
anab
Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
High
Report
Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
5/9
04:24 pm
anab
Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP) [Yahoo! Finance]
High
Report
Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP) [Yahoo! Finance]
5/9
04:24 pm
anab
Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties [Yahoo! Finance]
High
Report
Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties [Yahoo! Finance]
5/9
04:15 pm
anab
Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update
High
Report
Anaptys Announces First Quarter 2024 Financial Results and Provides Business Update
5/9
04:10 pm
anab
Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
High
Report
Anaptys Announces Positive Top-Line GEMINI-2 Phase 3 Clinical Trial Results of Imsidolimab (IL-36R) in Generalized Pustular Psoriasis (GPP)
5/9
04:05 pm
anab
Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties
High
Report
Anaptys to Receive $50 Million in a Capped Non-Recourse Monetization from Amended Agreement with Sagard in Exchange for Additional Jemperli Royalties
5/3
06:48 am
anab
Hidradenitis Suppurativa Pipeline Analysis Report 2024: Featuring 24+ Companies and 24+ Pipeline Drugs Including Vilobelimab (InflaRx), Secukinumab (Novartis), Avacopan (Chemo Centryx), Imsidolimab (AnaptysBio) [Yahoo! Finance]
Low
Report
Hidradenitis Suppurativa Pipeline Analysis Report 2024: Featuring 24+ Companies and 24+ Pipeline Drugs Including Vilobelimab (InflaRx), Secukinumab (Novartis), Avacopan (Chemo Centryx), Imsidolimab (AnaptysBio) [Yahoo! Finance]
5/1
06:19 am
anab
AnaptysBio (ANAB) Soars 14.3%: Is Further Upside Left in the Stock? [Yahoo! Finance]
Medium
Report
AnaptysBio (ANAB) Soars 14.3%: Is Further Upside Left in the Stock? [Yahoo! Finance]
4/24
09:12 am
anab
Actym Therapeutics Appoints Thomas Smart as CEO [Yahoo! Finance]
Low
Report
Actym Therapeutics Appoints Thomas Smart as CEO [Yahoo! Finance]
4/24
09:00 am
anab
Actym Therapeutics Appoints Thomas Smart as CEO
Low
Report
Actym Therapeutics Appoints Thomas Smart as CEO
4/18
05:33 am
anab
AnaptysBio, Inc. (NASDAQ: ANAB) had its "outperform" rating re-affirmed by analysts at Leerink Partnrs.
Medium
Report
AnaptysBio, Inc. (NASDAQ: ANAB) had its "outperform" rating re-affirmed by analysts at Leerink Partnrs.
4/16
08:09 am
anab
AnaptysBio, Inc. (NASDAQ: ANAB) is now covered by analysts at SVB Leerink LLC. They set an "outperform" rating and a $47.00 price target on the stock.
Low
Report
AnaptysBio, Inc. (NASDAQ: ANAB) is now covered by analysts at SVB Leerink LLC. They set an "outperform" rating and a $47.00 price target on the stock.
4/12
07:08 pm
anab
Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week [Yahoo! Finance]
Medium
Report
Why AnaptysBio Stock Zoomed Nearly 8% Higher This Week [Yahoo! Finance]
4/11
07:28 am
anab
AnaptysBio, Inc. (NASDAQ: ANAB) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $56.00 price target on the stock.
High
Report
AnaptysBio, Inc. (NASDAQ: ANAB) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $56.00 price target on the stock.
4/1
10:15 am
anab
AnaptysBio, Inc. (NASDAQ: ANAB) had its price target lowered by analysts at JPMorgan Chase & Co. from $30.00 to $28.00. They now have a "neutral" rating on the stock.
Low
Report
AnaptysBio, Inc. (NASDAQ: ANAB) had its price target lowered by analysts at JPMorgan Chase & Co. from $30.00 to $28.00. They now have a "neutral" rating on the stock.
3/18
07:02 am
anab
Industry Analysts Just Made A Stunning Upgrade To Their AnaptysBio, Inc. (NASDAQ:ANAB) Revenue Forecasts [Yahoo! Finance]
Low
Report
Industry Analysts Just Made A Stunning Upgrade To Their AnaptysBio, Inc. (NASDAQ:ANAB) Revenue Forecasts [Yahoo! Finance]
3/16
11:28 am
anab
Jemperli Cancer Drug: What To Know As GSK Says It Improves Survival For Uterine Cancer Patients [Forbes]
Low
Report
Jemperli Cancer Drug: What To Know As GSK Says It Improves Survival For Uterine Cancer Patients [Forbes]
3/16
08:15 am
anab
Positive RUBY phase III data show potential for Jemperli (dostarlimab-gxly) combinations in more patients with primary advanced or recurrent endometrial cancer [Yahoo! Finance]
Low
Report
Positive RUBY phase III data show potential for Jemperli (dostarlimab-gxly) combinations in more patients with primary advanced or recurrent endometrial cancer [Yahoo! Finance]
3/12
07:26 am
anab
AnaptysBio, Inc. (NASDAQ: ANAB) was upgraded by analysts at Wedbush from a "neutral" rating to an "outperform" rating. They now have a $34.00 price target on the stock, up previously from $20.00.
Medium
Report
AnaptysBio, Inc. (NASDAQ: ANAB) was upgraded by analysts at Wedbush from a "neutral" rating to an "outperform" rating. They now have a $34.00 price target on the stock, up previously from $20.00.
3/11
04:27 pm
anab
Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]
High
Report
Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update [Yahoo! Finance]
3/11
04:15 pm
anab
Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
High
Report
Anaptys Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
2/29
09:15 am
anab
Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting
Low
Report
Anaptys to Present at TD Cowen’s 44th Annual Health Care Conference and 2024 AAD Annual Meeting
2/28
11:25 am
anab
AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Should You Buy? [Yahoo! Finance]
Low
Report
AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Should You Buy? [Yahoo! Finance]